WAM
ESPR

Wolverine Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Wolverine Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$196 – 1853
2023
Q3 		$196 Hold
200
– – ﹤0.01% 1802
2023
Q2 		$278 Hold
200
– – ﹤0.01% 1719
2023
Q1 		$318 Buy
+200
New +$1.03K ﹤0.01% 1785
2022
Q3 		– Sell
-27,800
Closed -$176K – 2416
2022
Q2 		$176K Sell
27,800
-4,300
-13% -$24.4K ﹤0.01% 1233
2022
Q1 		$148K Buy
32,100
+22,800
+245% +$97.8K ﹤0.01% 1224
2021
Q4 		$46K Buy
9,300
+7,000
+304% +$56K ﹤0.01% 1532
2021
Q3 		$27K Buy
2,300
+1,100
+92% +$16K ﹤0.01% 1563
2021
Q2 		$25K Hold
1,200
– – ﹤0.01% 1854
2021
Q1 		$33K Buy
+1,200
New +$35.4K ﹤0.01% 1704

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wolverine Asset Management's ESPR Position: Q4 2025 in Review

Wolverine Asset Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 88,906 shares — an estimated $236K sold.

Wolverine Asset Management first reported a position in ESPR in Q2 2021 and held it in 18 quarters. The position peaked at $1.59M in Q2 2021. 201 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Wolverine Asset Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 88,906 Esperion Therapeutics shares in Q4 2025, an estimated $236K.
  • Wolverine Asset Management first reported a position in Esperion Therapeutics in Q2 2021 and held it in 18 quarters.
  • Wolverine Asset Management's Esperion Therapeutics position peaked at $1.59M in Q2 2021.
  • 201 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Wolverine Asset Management's 13F filing for Q4 2025, filed 2 Feb 2026.